This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Investigating Illumina's new PromoterAI platform for diagnosing rare genetic diseases.
Ticker(s): ILMNWho's the expert?
Institution: IQVIA
- VP of new offerings at IQVIA
- Develops go-to-market model, including development of marketing strategy and training for sales teams. Focused on Omnichannel engagement, supported by suggestion engines driven by both artificial intelligence / machine learning and rules-based algorithms.Defining new offerings and developing their go-to-market model, including development of marketing strategy and training for sales teams. Focused on Omnichannel engagement, supported by suggestion engines driven by both artificial intelligence / machine learning and rules-based algorithms.
Interview Goaldiscussing the potential of AI algorithms as a tool for diagnosing rare genetic diseases. Specifically, our client would like to discuss Illumina's new PromoterAI platform for diagnosing rare genetic diseases.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
